IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline

被引:40
作者
Scott, George [1 ]
Asrat, Seblewongel [1 ]
Allinne, Jeanne [1 ]
Lim, Wei Keat [1 ]
Nagashima, Kirsten [1 ]
Birchard, Dylan [1 ]
Srivatsan, Subhashini [1 ]
Ajithdoss, Dharani K. [1 ]
Oyejide, Adelekan [1 ]
Ben, Li-Hong [1 ]
Walls, Johnathon [1 ]
Le Floc'h, Audrey [1 ]
Yancopoulos, George D. [1 ]
Murphy, Andrew J. [1 ]
Sleeman, Matthew A. [1 ]
Orengo, Jamie M. [1 ]
机构
[1] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
关键词
IL-4; IL-13; Airway inflammation; Asthma; House dust mite; Lung remodeling; Anti-IL-5; Anti-IL-4R; Type; 2; inflammation; EPITHELIAL BARRIER DYSFUNCTION; RECEPTOR-ALPHA; ANTI-INTERLEUKIN-5; RECEPTOR; DOUBLE-BLIND; TH2; CELLS; ASTHMA; EXPRESSION; MEPOLIZUMAB; BENRALIZUMAB; MULTICENTER;
D O I
10.1016/j.cyto.2022.156091
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Rationale: Type 2 (T2) asthma is characterized by airflow limitations and elevated levels of blood and sputum eosinophils, fractional exhaled nitric oxide, IgE, and periostin. While eosinophils are associated with exacerbations, the contribution of eosinophils to lung inflammation, remodeling and function remains largely hypothetical. Objectives: To determine the effect of T2 cytokines IL-4, IL-13 and IL-5 on eosinophil biology and compare the impact of depleting just eosinophils versus inhibiting all aspects of T2 inflammation on airway inflammation. Methods: Human eosinophils or endothelial cells stimulated with IL-4, IL-13 or IL-5 were assessed for gene changes or chemokine release. Mice exposed to house dust mite extract received anti-IL-4R alpha (dupilumab), antiIL-5 or control antibodies and were assessed for changes in lung histological and inflammatory endpoints. Measurements and main results: IL-4 or IL-13 stimulation of human eosinophils and endothelial cells induced gene expression changes related to granulocyte migration; whereas, IL-5 induced changes reflecting granulocyte differentiation. In a mouse model, blocking IL-4R alpha improved lung function by impacting multiple effectors of inflammation and remodeling, except peripheral eosinophil counts, thereby disconnecting blood eosinophils from airway inflammation, remodeling and function. Blocking IL-5 globally reduced eosinophil counts but did not impact inflammatory or functional measures of lung pathology. Whole lung transcriptome analysis revealed that IL-5 or IL-4R alpha blockade impacted eosinophil associated genes, whereas IL-4R alpha blockade also impacted genes associated with multiple cells, cytokines and chemokines, mucus production, cell:cell adhesion and vascular permeability. Conclusions: Eosinophils are not the sole contributor to asthma pathophysiology or lung function decline and emphasizes the need to block additional mediators to modify lung inflammation and impact lung function.
引用
收藏
页数:13
相关论文
共 73 条
  • [1] Intravascular staining for discrimination of vascular and tissue leukocytes
    Anderson, Kristin G.
    Mayer-Barber, Katrin
    Sung, Heungsup
    Beura, Lalit
    James, Britnie R.
    Taylor, Justin J.
    Qunaj, Lindor
    Griffith, Thomas S.
    Vezys, Vaiva
    Barber, Daniel L.
    Masopust, David
    [J]. NATURE PROTOCOLS, 2014, 9 (01) : 209 - 222
  • [2] Chronic allergen exposure drives accumulation of long-lived IgE plasma cells in the bone marrow, giving rise to serological memory
    Asrat, Seblewongel
    Kaur, Navneet
    Liu, Xia
    Ben, Li-Hong
    Kajimura, Daisuke
    Murphy, Andrew J.
    Sleeman, Matthew A.
    Limnander, Andre
    Orengo, Jamie M.
    [J]. SCIENCE IMMUNOLOGY, 2020, 5 (43)
  • [3] Pulmonary Vasculature and Critical Asthma Syndromes: a Comprehensive Review
    Avdalovic, Mark
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2015, 48 (01) : 97 - 103
  • [4] Global strategy for asthma management and prevention: GINA executive summary
    Bateman, E. D.
    Hurd, S. S.
    Barnes, P. J.
    Bousquet, J.
    Drazen, J. M.
    FitzGerald, M.
    Gibson, P.
    Ohta, K.
    O'Byrne, P.
    Pedersen, S. E.
    Pizzichini, E.
    Sullivan, S. D.
    Wenzel, S. E.
    Zar, H. J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (01) : 143 - 178
  • [5] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
    Bel, Elisabeth H.
    Wenzel, Sally E.
    Thompson, Philip J.
    Prazma, Charlene M.
    Keene, Oliver N.
    Yancey, Steven W.
    Ortega, Hector G.
    Pavord, Ian D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) : 1189 - 1197
  • [6] Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study
    Bjermer, Leif
    Lemiere, Catherine
    Maspero, Jorge
    Weiss, Sivan
    Zangrilli, James
    Germinaro, Matthew
    [J]. CHEST, 2016, 150 (04) : 789 - 798
  • [7] Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
    Bleecker, Eugene R.
    FitzGerald, J. Mark
    Chanez, Pascal
    Papi, Alberto
    Weinstein, Steven F.
    Barker, Peter
    Sproule, Stephanie
    Gilmartin, Geoffrey
    Aurivillius, Magnus
    Werkstrom, Viktoria
    Goldman, Mitchell
    [J]. LANCET, 2016, 388 (10056) : 2115 - 2127
  • [8] Airway subepithelial fibrosis in a murine model of atopic asthma - Suppression by dexamethasone or anti-interleukin-5 antibody
    Blyth, DI
    Wharton, TF
    Pedrick, MS
    Savage, TJ
    Sanjar, S
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2000, 23 (02) : 241 - 246
  • [9] CD23 AND B-CELL ACTIVATION
    BONNEFOY, JY
    LECOANETHENCHOZ, S
    AUBRY, JP
    GAUCHAT, JF
    GRABER, P
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1995, 7 (03) : 355 - 359
  • [10] EOSINOPHIL TISSUE MOBILIZATION IN ALLERGIC DISORDERS
    BRUIJNZEEL, PLB
    [J]. CELLS AND CYTOKINES IN LUNG INFLAMMATION, 1994, 725 : 259 - 267